Table 1.
Characteristics of the patients.
| FMiS-negative group |
FMiS-positive group |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Therapies for |
Therapies for |
||||||||||||
| Case | No. | Sex | Age | Diagnosis | OP | RA | Case | No. | Sex | Age | Diagnosis | OP | RA |
| 1 | 1 | F | 64 | RA, FN | MTX, TAC | 1 | 12 | F | 27 | OA; trauma | |||
| 2 | 2 | F | 87 | RA, OP | BP | BUC | 2 | 13 | F | 43 | RA, OP | BP | ETN, MTX, PSL |
| 3 | 3 | F | 76 | RA, FN, OP | BP | MTX, SASP | 3 | 14 | F | 57 | RA | TCZ | |
| 4 | 4 | M | 78 | RA | BUC, PSL | 3 | 15 | F | 57 | RA | TCZ | ||
| 5 | 5 | F | 77 | RA, FN, OP | BP | SASP, PSL | 4 | 16 | F | 62 | RA | PSL | |
| 6 | 6 | F | 55 | RA, OP | BP | MTX, BUC, PSL | 5 | 17 | F | 73 | RA, FN | PSL | |
| 7 | 7 | M | 56 | FN | 6 | 18 | F | 77 | FN, OP | BP | |||
| 8 | 8 | F | 86 | FN, OP | Vit.D | 7 | 19 | F | 80 | RA, OP | BP | BUC, PSL | |
| 9 | 9 | F | 75 | FN, OP | 8 | 20 | F | 82 | RA, OP | BP | ETN, MTX, PSL | ||
| 10 | 10 | M | 83 | FN, OP | 9 | 21 | M | 60 | RA; excluded | MTX | |||
| 11 | 11 | F | 90 | FN, OP | |||||||||
FMiS, forming minimodeling structure; No., number of specimens; F, female; M, male; RA, rheumatoid arthritis; FN, femoral neck fracture; OA, osteoarthritis; OP, osteoporosis; BP, bisphosphonate; Vit.D, vitamin D; MTX, methotrexate; TAC, tacrolimus; BUC, bucillamine; SASP, sulfasalazine; PSL, prednisolone; IFX, infliximab; ETN, etanercept; TCZ, tocilizumab.